NasdaqGM:OMERPharmaceuticals
Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects
What recent performance signals for Omeros (OMER)
Without a single defining headline driving trading, Omeros (OMER) has still drawn attention after a strong month and past 3 months, alongside sizeable 1 year and 3 year total returns.
At a recent price of $14.83 and a market cap of about $1.06b, the stock reflects a clinical stage pipeline built around immunologic and rare disease programs rather than current product revenue.
See our latest analysis for Omeros.
For context, Omeros has paired a...